A solid platform with unique business model
- Leading market positions – Largest pharma company in MENA1, 7th largest generic pharma company in US2, Sixth largest generic injectable supplier in Europe3
- Expanding manufacturing footprint - 29 plants across our markets, with additional facilities being established
- Global player with local expertise
- Trusted partner known for our commitment to quality and reliability of supply
- Agile supply chain, flexible manufacturing and leading technical capabilities
Highlights
An increasingly diverse portfolio and pipeline
- A broad portfolio that is tailored to local market needs
- Growing presence in specialty, complex and higher-value products, which offer less competition and higher margins
- Strong momentum in new product launches across our markets
- Enhancing our pipeline by adding innovative products through value-creating partnerships
- Adding to the strength of our base business through strategic acquisitions
Highlights
Strategic execution driven by our three pillars
A proven track record of delivery for shareholders
- Group revenue compound annual growth rate (CAGR) of 7% and core EBIT CAGR of 6% since 2020
- Strong cash generation with $436m operating cash flow in 2025
- Strong balance sheet that provides financial flexibility to support future growth, with low leverage of 1.6x net debt to EBITDA
- High returns, with 16.0% return on average invested capital
Highlights
All figures for year ending 31 December 2025.
1. IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and the United Arab Emirates, MAT 2025
2. IQVIA MAT November 2025, includes all generic injectable and generic non-injectable products by sales
3. IQVIA Injectable generic products, Hospital + Germany Retail, 2024 USD sales
Latest news
Featured
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
Press Release, Financial Results
- Hikma appoints Rebecca Hall as Chief Financial Officer Press Release, Corporate 24 September 2026 Hikma appoints Rebecca Hall as Chief Financial Officer
- Hikma R&D Investor Spotlight Series Press Release, Corporate 22 September 2026 Hikma R&D Investor Spotlight Series
- Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia Press Release, Product 16 September 2026 Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia
- Hikma advances its epinephrine nasal spray with multi-market regulatory filings Press Release, Product 09 September 2026 Hikma advances its epinephrine nasal spray with multi-market regulatory filings
Related content